Incidence and prognostic impact of HER2-positivity loss after dual HER2-directed neoadjuvant therapy for HER2+ breast cancer.

ABSTRACT:

Background

Loss of HER2 "positivity" can occur in patients with residual disease after neoadjuvant treatment, but the incidence of HER2-positivity loss after neoadjuvant dual HER2-targeted treatment plus chemotherapy, the current standard-of-care for most early stage HER2-positive breast cancers, is not well described. Previous studies that report the HER2 discordance rate after neoadjuvant treatment also do not include the novel HER2-low category. In this retrospective study, we determine the incidence and prognostic impact of HER2-positivity loss, including the evolution to HER2-low disease, after neoadjuvant dual HER2-targeted therapy with chemotherapy.

Methods

Clinicopathologic data for patients with stage I-III HER2+ breast cancer diagnosed between 2015 and 2019 were re

SUBMITTER: LeVee A 

PROVIDER: S-EPMC10225224 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature